eISSN: 2081-2841
ISSN: 1689-832X
Journal of Contemporary Brachytherapy
Current Issue Archive Supplements Articles in Press Journal Information Aims and Scope Editorial Office Editorial Board Register as Author Register as Reviewer Instructions for Authors Abstracting and indexing Subscription Advertising Information Links
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
5/2020
vol. 12
 
Share:
Send email
Share:
abstract:
Original paper

Feasibility and early toxicity of focal or partial brachytherapy in prostate cancer patients

Tae Heon Kim
1
,
Jong Nyeong Kim
1
,
Young Dong Yu
1
,
Seung Ryeol Lee
1
,
Young Kwon Hong
1
,
Hyun Soo Shin
2
,
Dong Soo Park
1

  1. Department of Urology, CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea
  2. Department of Radiation Oncology, CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea
J Contemp Brachytherapy 2020; 12, 5: 420–426
DOI: https://doi.org/10.5114/jcb.2020.100374
Online publish date: 2020/10/30
View full text Get citation
 
Introduction
The aim of this study was to compare short-term oncologic outcomes and toxicity of focal or partial low-dose-rate brachytherapy (focal/partial LDR-BT) with whole gland low-dose-rate brachytherapy (whole LDR-BT) in localized prostate cancer patients.

Material and methods
Medical records of eligible patients who underwent focal/partial LDR-BT and whole LDR-BT between 2015 and 2017 at our institution were reviewed retrospectively. Clinical characteristics and pathologic outcomes were compared between focal/partial LDR-BT group and whole LDR-BT group. Biochemical recurrence-free survival was analyzed using Kaplan-Meier method and difference between two groups was assessed with log-rank test. Genitourinary and rectal toxicity were also evaluated between the two groups.

Results
Of the 60 patients analyzed, 30 focal/partial LDR-BT patients and 30 whole LDR-BT brachytherapy patients were included. Relative to the whole LDR-BT group, the focal/partial LDR-BT group had significantly higher initial PSA level (p = 0.002), smaller number of implanted seeds (p < 0.001), and shorter follow-up duration (p < 0.001). There was no significant difference between the two groups with regard to prostate volume, biopsy Gleason score, and risk group stratification. The 3-year biochemical recurrence-free survival estimates for focal/partial LDR-BT group and whole LDR-BT group were 91.8% and 89.6%, respectively, which was not significantly different (p = 0.554). Genitourinary symptoms were significantly worse in whole LDR-BT group than in focal/partial LDR-BT group. The incidence of rectal toxicity was similar between two groups.

Conclusions
Our findings indicate that the focal/partial LDR-BT is comparable to the whole LDR-BT with respect to short-term biochemical recurrence and toxicities.

keywords:

prostate cancer, brachytherapy, focal therapy, biochemical recurrence, toxicity

  
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.